Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.78 USD

73.78
5,148,046

-0.56 (-0.75%)

Updated Aug 16, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?

Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?

For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.

Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $65.15 in the latest trading session, marking a +1.57% move from the prior day.

Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?

Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GILD vs. ALKS: Which Stock Is the Better Value Option?

GILD vs. ALKS: Which Stock Is the Better Value Option?

Sweta Jaiswal, FRM headshot

Will Biotech ETFs Continue to Rally in Q1 Earnings?

Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?

AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.

Sweta Killa headshot

Can Q1 Earnings Lift Healthcare ETFs Higher?

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

Gilead Collaborates With Insitro to Develop NASH Therapies

Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).

Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $65.39, marking a +0.17% move from the previous day.

Gilead to Collaborate with Novo Nordisk for NASH Treatment

Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.

Intercept Reports Additional Positive Data From NASH Study

Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.

Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients

Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $67.38, marking a -0.24% move from the previous day.